Start-ups supported by EIT Health Germany progress to European Health Catapult Final Competition

After winning regional pre-selection, Medical Magnesium and SensArs succeed at European Semi-Finals

EIT Health Germany is proud to announce that two of its start-ups, Medical Magnesium and SensArs, are among the eight start-ups who will compete at the EIT Health Summit on 4-5 December 2018, in Lódz.

Attend the EIT Health Summit to cheer for them as they pitch in the final competition!

The selected start-ups are:

German and Swiss start-ups:

• Medical Magnesium GmbH (EIT Health Germany) – Medical Magnesium is a medtech start-up that revolutionises modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. Medical Magnesium has developed a new class of bioabsorbable implants that eliminate the need for a removal surgery, as they absorb in a controlled manner after healing the fracture. Together with leading users from orthopedics and trauma surgery the team strives for a better patient care.
  Contact person: Florian Coppers, CEO – coppers@medical-magnesium.com

• SensArs Neuroprosthetics (EIT Health Germany) – SensArs has developed SENSY, unique worldwide device to restore sensory feedback to lower limb amputees from their prosthesis. SensArs has also conducted a pilot trial with three lower limb amputees, preliminarily proving that SENSY reduces the risk of falls, increases the perception of the prosthesis as part of the body, and diminishes phantom limb pain.
  Contact person: Francesco Petrini, PhD – francesco.petrini@sensars.com

Other start-ups:

• Aenitis Technologies (EIT Health France) – Cost effective and efficient Bioprocessing solutions are main issues in cell therapy. Aenitis develop innovative patented medical devices for continuous, contactless and pressurless sorting of cells in suspensions, using Acoustic Radiation Forces. Contact person: Emmanuel Vincent – emmanuel.vincent@aenitis.fr

• HydrUStent, LDA (EIT Health Innostars) – Every year around ten million people worldwide need a urological STENT. HydrUStent is a biodegradable, anti-bacterial and tailor-made stent which underlying technology has been protecting by a patent. HydrUStent not only reduces the risk of bacterial infection but it also cuts down half the number of surgical procedures reducing the treatment cost by 60%.
  Contact person: Alexandre Barros – abarros@hydrustent.com

• INGA Wellbeing (EIT Health BENE) – To counter the debilitating impact of the hospital gown, INGA Wellbeing worked with nurses to create award-winning day- and nightwear that accommodates with IV lines, drains and monitors. Able to dress themselves, patients feel in control and are more likely to walk and enjoy visitors and thus improve their wellbeing and recovery. Contact person: Nikla Lancksweert – nikla@ingawellbeing.com

• Plasmacure B.V.(EIT Health BENE) – Around ten million patients in Europe develop diabetic foot, venous leg and pressure ulcers. For 3% of diabetic foot patients these wounds result in an amputation. This decreases quality of life for patients. Our goal is to prevent this and heal wounds with Plasoma. Plasoma is a chronic wound healing device consisting of an electronic pad that creates a cold plasma in the wound and a pulser that sends the electric current to the pad. When applied to the wound the cold plasma kills the bacteria and stimulates healing.
  Contact person: Bas Zeper – bas.zeper@plasmacure.nl

• SensArs Neuroprosthetics (EIT Health Germany) – SensArs has developed SENSY, unique worldwide device to restore sensory feedback to lower limb amputees from their prosthesis. SensArs has also conducted a pilot trial with three lower limb amputees, preliminarily proving that SENSY reduces the risk of falls, increases the perception of the prosthesis as part of the body, and diminishes phantom limb pain.
  Contact person: Francesco Petrini, PhD – francesco.petrini@sensars.com

• VitaDX International (EIT Health France) – VitaDX combines fluorescence imaging and image processing using machine learning algorithms to detect cancerous cells in a urine sample. Our clinical trial on 1400 patients will end in early 2019 and the first solution, VisioCyt, will be commercialized in early 2020. We have fundraised €2.6 M in two turns of financing with business angels and Venture Capitalists and are looking for 3 M€ in early 2019.
  Contact person: Allan Rodriguez – allan@vitadx.com

• TADA Medical (EIT Health Scandinavia) – Global statistics show that 10% of medical tubes are accidentally pulled and damaged, resulting in loss of medicine, patient injury and possibly death. TADA Medical has invented a fail-safe connector made to keep the tube, patient and personnel safe. Our connector is cheap and mass producible, perfect for protecting the 3.5 billion tubes currently at risk of being pulled. The market is estimated to €7 billion a year.
  Contact person: Katarina Hedbeck, CEO – katarina.hedbeck@tadamedical.com

Download the document below for more information about each start-up.

Click here to learn more about the EIT Health Summit.

Sign up if you would like to attend the summit.